Skip to main content

Advertisement

Log in

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience

  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Familial pancreatic cancer (FPC) is a rare hereditary tumor syndrome. The 10-years experience of the national case collection for familial pancreatic cancer of Germany (FaPaCa) is reported. Since 1999 FaPaCa has collected families with at least two first-degree relatives with confirmed pancreatic cancer (PC), who did not fulfill the criteria of other hereditary tumor syndromes. Histopathological verification of tumor diagnoses, and genetic counseling were prerequisites for enrollment of families in FaPaCa. 94 of 452 evaluated families fulfilled the criteria for partaking in FaPaCa. PC represented the sole tumor entity in 38 (40%) families. In 56 families additional tumor types occurred, including breast cancer (n = 28), colon cancer (n = 20) and lung cancer (n = 11). In 70 (74%) families the pattern of inheritance was consistent with an autosomal dominant trait. Compared to the preceding generation, a younger age of onset was observed in the offspring of PC patients (median: 57 vs. 69 years), indicating anticipation. Mutation analyses of BRCA2, PALB2, CDKN2a, RNASEL, STK11, NOD2, CHEK2 and PALLD, revealed deleterious causative germline mutations of BRCA2 and PALB2 in 2 of 70 (3%) and 2 of 41 (4.9%) German FPC families, respectively. Prospective PC screening with EUS, MRI and MRCP detected precancerous lesions (IPMN, multifocal PanIN2/3) or carcinoma in 5.5% (4 of 72) to 12.5% (9 of 72) of individuals at risk, depending on histological verification. Appropriate inclusion of families at high risk for PC in registries, such as FaPaCa, provides a unique and excellent tool to gain clinical and genetic knowledge of FPC. Focused research projects can be conducted most efficiently, when data of different FPC registries are combined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cooperman AM (2001) Pancreatic cancer: the bigger picture. Surg Clin North Am 81:557–574

    Article  PubMed  CAS  Google Scholar 

  2. Cleary SP, Gryfe R, Guindi M et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731

    Article  PubMed  Google Scholar 

  3. Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23

    PubMed  CAS  Google Scholar 

  4. Lynch HT, Brand RE, Deters CA et al (2001) Hereditary pancreatic cancer. Pancreatology 1:466–471

    Article  PubMed  CAS  Google Scholar 

  5. Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588 viii

    Article  PubMed  CAS  Google Scholar 

  6. Ehrenthal D, Haeger L, Griffin T et al (1987) Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59:1661–1664

    Article  PubMed  CAS  Google Scholar 

  7. MacDermott RP, Kramer P (1973) Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65:137–139

    PubMed  CAS  Google Scholar 

  8. Reimer RR, Fraumeni JF Jr, Ozols RF et al (1977) Pancreatic cancer in father and son. Lancet 1:911

    Article  PubMed  CAS  Google Scholar 

  9. Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr et al (1989) Familial pancreatic cancer (part 1): genetic pathology review. Nebr Med J 74:109–112

    PubMed  CAS  Google Scholar 

  10. Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516

    Article  PubMed  CAS  Google Scholar 

  11. Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744

    PubMed  CAS  Google Scholar 

  12. Hruban RH, Petersen GM, Goggins M et al (1999) Familial pancreatic cancer. Ann Oncol 10(Suppl 4):69–73

    Article  PubMed  Google Scholar 

  13. Bartsch DK, Kress R, Sina-Frey M et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110:902–906

    Article  PubMed  CAS  Google Scholar 

  14. Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103:525–530

    Article  PubMed  CAS  Google Scholar 

  15. Hahn SA, Greenhalf B, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221

    Article  PubMed  CAS  Google Scholar 

  16. Bartsch DK, Fendrich V, Slater EP et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718–722

    Article  PubMed  CAS  Google Scholar 

  17. Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5:305–308

    Article  PubMed  CAS  Google Scholar 

  18. Bartsch DK, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737

    Article  PubMed  Google Scholar 

  19. Grutzmann R, McFaul C, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63–68

    Article  PubMed  Google Scholar 

  20. Nej K, Bartsch DK, Sina-Frey M et al (2004) The NOD23020insC mutation and the risk of familial pancreatic cancer? Hered Cancer Clin Pract 2:149–150

    Article  PubMed  Google Scholar 

  21. Slater E, Amrillaeva V, Fendrich V et al (2007) Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 4:e164

    Article  PubMed  Google Scholar 

  22. Slater EP, Langer P, Habbe N et al. (2010) Prevalence of PALB2 mutations in familial pancreatic cancer. Clin Genet (in press)

  23. Bartsch DK, Langer P, Habbe N et al. (2009) Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. Clin Genet 77:333–341

    Article  PubMed  Google Scholar 

  24. McFaul CD, Greenhalf W, Earl J et al (2006) Anticipation in familial pancreatic cancer. Gut 55:252–258

    Article  PubMed  CAS  Google Scholar 

  25. Slater EP, Langer P, Fendrich V et al. (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9:335–343

    Article  PubMed  CAS  Google Scholar 

  26. Langer P, Kann PH, Fendrich V et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410–1418

    Article  PubMed  CAS  Google Scholar 

  27. Lynch HT, Fusaro L, Smyrk TC et al (1995) Medical genetic study of eight pancreatic cancer-prone families. Cancer Invest 13:141–149

    Article  PubMed  CAS  Google Scholar 

  28. Greenhalf W, Malats N, Nilsson M et al (2008) International registries of families at high risk of pancreatic cancer. Pancreatology 8:558–565

    Article  PubMed  Google Scholar 

  29. Schuz J, Schon D, Batzler W et al (2000) Cancer registration in Germany: current status, perspectives and trends in cancer incidence 1973–93. J Epidemiol Biostat 5:99–107

    PubMed  CAS  Google Scholar 

  30. Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793

    PubMed  CAS  Google Scholar 

  31. Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342–346

    Article  CAS  Google Scholar 

  32. Jones S, Hruban RH, Kamiyama M et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217

    Article  PubMed  CAS  Google Scholar 

  33. Pogue-Geile KL, Chen R, Bronner MP et al (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3:e516

    Article  PubMed  Google Scholar 

  34. Earl J, Yan L, Vitone LJ et al (2006) Evaluation of the 4q32–34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomark Prev 15:1948–1955

    Article  CAS  Google Scholar 

  35. Brand RE (2009) Screening for familial pancreatic cancer: is doing something better than doing nothing? Gut 58:1321–1322

    Article  PubMed  Google Scholar 

  36. Canto MI, Goggins M, Yeo CJ et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2:606–621

    Article  PubMed  Google Scholar 

  37. Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781

    Article  PubMed  Google Scholar 

  38. Poley JW, Kluijt I, Gouma DJ et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181

    Article  PubMed  CAS  Google Scholar 

  39. Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 6:437–445

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to all FPC families for participating in the registry. This study was supported by grants 70-2362-Ba2, 70-2828-Ba3 and 103709 of the Deutsche Krebshilfe.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Langer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, R., Slater, E.P., Sina, M. et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Familial Cancer 10, 323–330 (2011). https://doi.org/10.1007/s10689-010-9414-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-010-9414-x

Keywords

Navigation